Pacific Edge Raises $20.7 Million in Successful Capital Raise

Pacific Edge Limited ( (PFGTF) ) has shared an announcement.

Pacific Edge Limited has successfully closed its Share Purchase Plan (SPP), raising approximately $4.7 million, which, combined with a $16.1 million Placement, brings the total new equity to $20.7 million. This capital raise exceeds the initially targeted $20 million due to oversubscriptions. The funds are contingent on shareholder approval at the upcoming Annual Shareholders’ Meeting and are expected to enhance the company’s financial position, potentially impacting its market operations and stakeholder interests positively.

More about Pacific Edge Limited

Pacific Edge Limited is a global cancer diagnostics company specializing in the development and commercialization of bladder cancer diagnostic and prognostic tests. Headquartered in Dunedin, New Zealand, the company offers its Cxbladder suite of non-invasive genomic urine tests, which are designed for the risk stratification of urothelial cancer. These tests are available globally, including in the US, Australasia, Israel, and various markets in Asia and South America.

For detailed information about PFGTF stock, go to TipRanks’ Stock Analysis page.